Treating Amyotrophic Lateral Sclerosis (ALS) With R(+) Pramipexole Dihydrochloride Monohydrate at 60 mg/Day

• Status: Temporarily not available
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

R(+) pramipexole dihydrochloride monohydrate [R(+)PPX], an experimental neuroprotective drug, is provided in this open label extension study to ALS patients who have participated in earlier clinical protocols.

Details

• Lead Sponsor: Bennett, James P., Jr., M.D., Ph.D.
• Collaborators: University of Nebraska; University of Pittsburgh
• Treatments: Pramipexole

Criteria

Inclusion Criteria:

• Definite diagnosis of ALS

Exclusion Criteria:

• No prior participation in R(+)PPX clinical studies